The Latest Cardiac and Vascular News
CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended March 31, 2023 and provided a business update. First Quarter 2023 and Recent Corporate and Operational Highlights Continued reducing expenses to conserve cash […]
CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that the Company has been granted a clinical Type B meeting with the U.S. Food & Drug Administration (FDA). The Company was previously granted Regenerative Medicine Advanced Therapy (RMAT) and […]
Enrollment completed in second cohort of MATRICS-1 trial in hemorrhagic trauma Enrollment reaches halfway mark in MASTERS-2 trial in ischemic stroke CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of […]
Corporate restructuring underway and MASTERS-2 clinical trial prioritized Conference call begins at 4:30 p.m. Eastern time today CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate […]
TREASURE topline results show evidence of therapeutic impact Study preliminary results analyses indicate good potential for favorable results in Athersys’ MASTERS-2 study Conference call today at 8:30 a.m. ET CLEVELAND, Ohio–(BUSINESS WIRE)–Athersys, Inc. (Nasdaq: ATHX) announced today that its partner, HEALIOS K.K. (Healios), has reported topline results for its Japan […]
Management to host conference call following announcement of Phase 2/3 TREASURE data in May CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2022. In anticipation of the announcement in May of topline data from Athersys’ partner, HEALIOS K.K. (Healios), for its […]
Camardo to lead Company’s transition to a commercial-stage company CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (Nasdaq: ATHX), an international, late-stage, regenerative medicine company, announced today the appointment of Daniel A. Camardo as the Company’s Chief Executive Officer, effective February 14, 2022. Mr. Camardo is a senior pharmaceutical and biotech executive with more than […]
